The Brazil profile in ClinRegs has been reviewed and updated to reflect the implementation of RDC No. 172 of 8 September 2017. This resolution states that ANVISA will analyze imported human biological samples and goods and products intended for use in human subject research within 48 hours of arriving in Brazil, provided that all legal requirements are met and that the purpose of the research is not to register or change the registration of a product.

For more information, see the Manufacturing & Import and Specimen Import & Export sections.